15 December 2025

Polarean Imaging Plc

("Polarean" or the "Company")

Result of General Meeting

Information on Matched Bargain Facility to assist shareholders

Polarean Imaging plc (AIM: POLX), a commercial-stage medical technology company and global leader in functional lung imaging using hyperpolarised Xenon MRI, announces that at the general meeting of the Company ("General Meeting") held earlier today, all resolutions were duly passed on a poll.

Details of the poll results are set out below:

*Note: A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.

Valid proxy instructions were received in respect of 664,456,630 Ordinary Shares representing approximately 55.05% of the issued share capital of the Company.

The total number of Ordinary Shares in issue as at 15 December 2025 is 1,207,032,781.

The full text of the Resolutions proposed and passed at the General Meeting can be found in the circular of the Company containing, inter alia, the notice of General Meeting, which was published on 14 November 2025 (the "Circular") and is available on the Company's website here. Capitalised terms used but not defined in this announcement shall have the same meaning given to such terms in the Circular.   

AIM Cancellation

Following approval by Shareholders at the General Meeting, the admission of the Ordinary Shares to trading on AIM will be cancelled. The Cancellation is expected to take place at 7:00 a.m. on 23 December 2025 and, accordingly, the last day of dealings in Ordinary Shares on AIM is expected to be 22 December 2025.

Re-registration as a private company

In accordance with the passing of Resolution 2, the Company will re-register as a private limited company and adopt new articles of association, which is expected to take place by 12 January 2026.

Matched Bargain Facility

The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation.

Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares.

The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders.

The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.

Enquiries:

About Polarean

Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.

For the latest news and information about Polarean, please visit the website at www.polarean.com